PSCR (Proto Script Pharmaceutical) Graham Number: $N/A (As of Sep. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Proto Script Pharmaceutical Graham Number?

Proto Script Pharmaceutical PSCR Graham Number is $N/A as of Sep. 2017.

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2026-08-20), the stock price of Proto Script Pharmaceutical is $0.0002. Proto Script Pharmaceutical's graham number for the quarter that ended in Sep. 2017 was $N/A. Therefore, Proto Script Pharmaceutical's Price to Graham Number ratio for today is N/A.

The historical rank and industry rank for Proto Script Pharmaceutical's Graham Number or its related term are showing as below:

PSCR's Price-to-Graham-Number is not ranked *
in the Business Services industry.
Industry Median: 1.16
* Ranked among companies with meaningful Price-to-Graham-Number only.

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


Proto Script Pharmaceutical  (OTCPK:PSCR) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

Proto Script Pharmaceutical's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Sep. 2017 )
=0.0002/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


Proto Script Pharmaceutical Graham Number Related Terms


Proto Script Pharmaceutical Graham Number Historical Data

* Premium members only.

The historical data trend for Proto Script Pharmaceutical's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Proto Script Pharmaceutical Graham Number Chart

Proto Script Pharmaceutical Annual Data
Trend May12 May13 May14 May15 May16
Graham Number
0.00 0.00 0.00 0.00 0.00

Proto Script Pharmaceutical Quarterly Data
Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Sep16 Dec16 Mar17 Jun17 Sep17
Graham Number Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PSCR vs EXCC, NXES, PRZM: Graham Number Comparison

For the Specialty Business Services subindustry, Proto Script Pharmaceutical's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Proto Script Pharmaceutical Price-to-Graham-Number vs Business Services Industry

For the Business Services industry and Industrials sector, Proto Script Pharmaceutical's Price-to-Graham-Number distribution charts can be found below:

* The bar in red indicates where Proto Script Pharmaceutical's Price-to-Graham-Number falls into.



Proto Script Pharmaceutical Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

Proto Script Pharmaceutical's Graham Number for the fiscal year that ended in May. 2016 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*-0.003*-0.001)
=N/A

Proto Script Pharmaceutical's Graham Number for the quarter that ended in Sep. 2017 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*-0.029*-0.024)
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Graham Number →
What does a Graham Number of $N/A mean?
Proto Script Pharmaceutical (PSCR) has a Graham Number of $N/A as of Sep. 2017. The Graham Number values a company based on its per-share earnings and book value. View historical data on Proto Script Pharmaceutical and its competitors.
Is Proto Script Pharmaceutical's Graham Number too high?
Proto Script Pharmaceutical's current Graham Number is $N/A.
How does Proto Script Pharmaceutical's Graham Number compare to EXCC and NXES?
Proto Script Pharmaceutical's Graham Number of $N/A can be compared against companies in the Business Services industry. The industry median Graham Number is 1.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Business Services company?
The median Graham Number among Business Services companies is 1.16, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Proto Script Pharmaceutical and its competitors. For the Business Services industry, the median Graham Number is 1.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proto Script Pharmaceutical's current Graham Number is $N/A. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proto Script Pharmaceutical stock overvalued right now?
Proto Script Pharmaceutical (PSCR) has a current Graham Number of $N/A. The current Graham Number is $N/A. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Proto Script Pharmaceutical (PSCR), the current Graham Number is $N/A as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Proto Script Pharmaceutical Business Description

Address 9830 6th Street, Suite 103, Rancho Cucamonga, CA, USA, 91730
Proto Script Pharmaceutical Corp is primarily in the business of repair power wheelchairs and scooters, which are classified as durable medical equipment (DME) products and reimbursable by healthcare insurance providers. It has various contracts with state and governmental insurance providers, among others. These contracts provide the company with the right to sell and repair DME and its health care insurance contracts allow it the ability to service patients nationally. The group currently has its presence of repair facilities in Las Vegas, Nevada, Rancho-Cucamonga, and Anaheim, California.